A novel topical nano-propranolol for treatment of infantile hemangiomas.
A novel topical nano-propranolol for treatment of infantile hemangiomas.
复制标题
DOI：
10.1016/j.nano.2015.02.015
复制
发表时间：
2015-07
期刊：
影响因子：
--
通讯作者：
Zheng-Gang Chen;Jia-wei Zheng;Minglu Yuan;Ling Zhang;Wei-En Yuan
中科院分区：
文献类型：
--
作者：
Zheng-Gang Chen;Jia-wei Zheng;Minglu Yuan;Ling Zhang;Wei-En Yuan
局部普萘洛尔已被用于治疗浅表性婴儿血管瘤（IH）。对50例患者进行回顾性研究，以评价新型局部纳米普萘洛尔分散水凝胶的临床效果。参与者每天接受3次治疗，持续2周至11个月。68%的患者为女性，12%的患者在治疗前接受过其他治疗。纳米普萘洛尔0.5%水凝胶开始时的平均年龄为5.010个月，平均持续时间为3.610个月。有效率为86%。停用后无复发和反弹生长。仅在2例病例中观察到轻微副作用（给药部位瘙痒、糜烂和结痂）。所有局部刺激均被评价为轻度，并且可耐受，无需停止用药。我们建议，局部纳米普萘洛尔水凝胶可能是一种替代选择，用于治疗简单的浅表IH，具有令人满意的耐受性和最佳effictiveness.From the Clinical EditorThe目前推荐的治疗婴儿血管瘤的方法是口服普萘洛尔。尽管如此，一小部分患者会出现全身性副作用。在这篇文章中，作者开发了局部纳米普萘洛尔水凝胶，并在临床患者中进行了测试，发现了良好的反应。
Topical propranolol has been used for the therapy of superficial infantile hemangiomas (IH). A retrospective investigation was conducted in 50 patients to evaluate the clinical effect of a new type of topical nano-propranolol-dispersed hydrogel. Participants were treated 3 times per day for 2 weeks to 11 months. 68% of patients were female and 12% had received other treatments before therapy. The nano-propranolol 0.5% hydrogel was initiated at a mean age of 5.010 months and for a mean duration of 3.610 months. The response rate was 86%. No recurrence and rebound growth occurred after withdrawal of hydrogel. Slight side effects (application site itching, erosion and crusting) were observed in only 2 cases. All the local irritations were evaluated as mild and were tolerated without discontinuing the medication. We suggest that topical nano-propranolol hydrogel could be an alternative option for the treatment of uncomplicated superficial IH with satisfactory tolerability and optimal effectiveness.From the Clinical EditorThe current recommended treatment for infantile hemangiomas is oral propranolol. Nonetheless, a small proportion of patients will have systemic side effects. In this article, the authors developed topical nano-propranolol hydrogel and tested this on clinical patients and found favorable response.